Cohort study
Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy
- Registry-based cohort study
- multicenter
- serial coronary CT angiography ≥2 years apart
Authors' conclusion
In patients treated with statins, baseline plaque characterization by plaque burden and HRP is associated with atherosclerotic statin nonresponse. Patients with the highest plaque burden including HRP were at highest risk for plaque progression, despite statin therapy.
Study context
- Population
- Statin-treated patients with serial coronary CT angiography ≥2 years apart (PARADIGM registry)
- Participants
- 649 patients
- Exposure
- Statin nonresponders vs responders
- Outcome
- Atherosclerotic statin nonresponse: absolute increase in percent atheroma volume (PAV) ≥1.0% per year
Main finding
As reported in the abstract
Atherosclerotic statin nonresponse (PAV increase ≥1.0%/year)
Odds ratio (95% CI)
Diabetes
1.41(0.95–2.11)
Number of HRP features
1.15(1.09–1.21)
Noncalcified PAV
1.06(1.02–1.10)
Calcified PAV
1.07(1.03–1.12)
- Patients with atherosclerotic statin nonresponse
- 205 (31.5%)
Observational data: associations, not effects.
Secondary outcomes
Secondary endpoint: nonresponse plus progression of low-attenuation or fibro-fatty plaque
| Comparison | OR (95% CI) | |
|---|---|---|
| Noncalcified PAV · independent determinant | 1.08 (1.03–1.13) | |
| Number of HRP features · independent determinant | 1.21 (1.06–1.21) | |
| 0.512Odds ratio (log scale) |
- Secondary endpoint: nonresponse plus progression of low-attenuation or fibro-fatty plaque — Patients meeting secondary endpoint
- 125, 19.2%
Original publication
Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy. JACC Cardiovasc Imaging. Published 14 December 2022. doi:10.1016/j.jcmg.2022.10.017
Summarised from the published abstract; every number is checked against it